SCHEMBL12499368

SCHEMBL12499368

NC(=O)C1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
OPRD1 P41143 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
KMT2A Q03164 5/20 0.47
NPSR1 Q6W5P4 2/20 0.47
SLC6A9 P48067 1/20 0.47
MAOB P27338 1/20 0.46
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
MEN1 O00255 2/20 0.44
CACNA2D1 P54289 2/20 0.44
CACNA1B Q00975 2/20 0.44
CACNB1 Q02641 2/20 0.44
CACNA1C Q13936 2/20 0.44
CACNA1H O95180 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85386 0.85 ALDH1A1 (0.54) ALDH1A1OPRD1CNR1CNR2KMT2A
SCHEMBL8478451 0.84 KMT2A (0.59) ALDH1A1OPRD1TDP1CNR1CNR2
SCHEMBL20594076 0.84 KMT2A (0.57) ALDH1A1OPRD1CNR1CNR2KMT2A
SCHEMBL8473590 0.83 ALDH1A1 (0.60) ALDH1A1OPRD1TDP1CNR1CNR2
SCHEMBL493492 0.82 TDP1 (0.52) ALDH1A1OPRD1TDP1CNR1CNR2
SCHEMBL3299615 0.81 MAOB (0.53) ALDH1A1OPRD1CNR1CNR2KMT2A
Hydrochloric Acid SCHEMBL4509686 0.81 ALDH1A1 (0.50) ALDH1A1OPRD1CNR1CNR2KMT2A
SCHEMBL5398185 0.79 OPRL1 (0.42) ALDH1A1OPRD1CNR1CNR2KMT2A
SCHEMBL16152958 0.79 OPRL1 (0.42) ALDH1A1OPRD1CNR1CNR2KMT2A
SCHEMBL5398188 0.79 OPRL1 (0.42) ALDH1A1OPRD1CNR1CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481670-B2 Triazine compounds SPHAERA PHARMA PTE. LTD. (SG) 2016-11-01 US disclosed
US-9481670-B2 Triazine compounds SPHAERA PHARMA PTE. LTD. (SG) 2016-11-01 US disclosed
US-9481670-B2 Triazine compounds SPHAERA PHARMA PTE. LTD. (SG) 2016-11-01 US disclosed
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS SPHAERA PHARMA PTE. LTD. (SG) 2013-11-14 US disclosed
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS SPHAERA PHARMA PTE. LTD. (SG) 2013-11-14 US disclosed
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS SPHAERA PHARMA PTE. LTD. (SG) 2013-11-14 US disclosed
WO-2012101654-A2 NOVEL TRIAZINE COMPOUNDS SPHAERA PHARMA PVT. LTD (IN) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS MTOR, MAPKAP1, PIK3R5 ALDH1A1 3791/4885OPRD1 3112/4885TDP1 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.